• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

Host Cell Protein Analysis in Biologics

01/09/2014 by Ana Arraztio No Comments

In a previous post, we looked at innovative methods to assess immunogenicity in biotherapeutics and biosimilars.

The objective though, is to have the least immunogenicity possible (exception made for vaccines). Some factors, especially those which are patient-related, cannot be always controlled but some can definitely be monitored during the production processes of biotherapeutics and biosimilars. Let’s take the case of  Host Cell Proteins (HCPs).

Continue reading
Supplying Discovery Tools

Immunogenicity in biotherapeutics and biosimilars

06/08/2014 by Ana Arraztio No Comments

Following on from my previous post on biosimilars and biotherapeutics (or biologics), let’s now take a look at some of the specific criteria for this kind of compound, which are not normally required for “classical” drugs. One of them is immunogenicity.

Immunogenicity is the ability of a given product to raise an immune response in an animal or a human. Biological products have this “tendency” to provoke this immune response, so this has to be carefully controlled. For vaccines, we are interested in getting high immunogenicity. For other biotherapies, though, immunogenicity should be as low as possible.

Continue reading

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com